Patent ID: 8906899

Claim:
A method of treating an immunosuppressant disorder associated with the sphingosine-1-phosphate receptor modulation, wherein the immunosuppressant disorder is selected from: rheumatoid arthritis, psoriasis, atherosclerosis, autoimmune uveitis, dry eye, inflammatory bowel diseases, atopic allergy, atopic dermatitis, contact dermatitis, multiple sclerosis, Sjogren's syndrome and organ transplant rejection, in a mammal in need thereof, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound represented by Formula I or a pharmaceutically acceptable salt thereof: wherein: A is C 6-10 aryl, heterocycle, C 3-8 cycloalkyl or C 3-8 cycloalkenyl; B is C 6-10 aryl, heterocycle, C 3-8 cycloalkyl or C 3-8 cycloalkenyl; R 1 is H, halogen, —OC 1-8 alkyl, C 1-8 alkyl, CN, C(O)R 9 , NR 10 R 11 or hydroxyl; R 2 is H, halogen, —OC 1-8 alkyl, C 1-8 alkyl, CN, C(O)R 9 , NR 10 R 11 or hydroxyl; R 3 is H, halogen, —OC 1-8 alkyl, C 1-8 alkyl, CN, C(O)R 9 , NR 10 R 11 or hydroxyl; R 4 is H, halogen, —OC 1-8 alkyl, C 1-8 alkyl, CN, C(O)R 9 , NR 10 R 11 or hydroxyl; R 5 is H, halogen, —OC 1-8 alkyl, C 1-8 alkyl, CN, C(O)R 9 , NR 10 R 11 or hydroxyl; R 6 is H, halogen, —OC 1-8 alkyl, C 1-8 alkyl, CN, C(O)R 9 , NR 10 R 11 or hydroxyl; R 7 is H, halogen, —OC 1-8 alkyl, C 1-8 alkyl, CN, C(O)R 9 , NR 10 R 11 or hydroxyl; R 8 is halogen, —OC 1-8 alkyl, C 1-8 alkyl, CN, C(O)R 9 , NR 10 R 11 or hydroxyl; L is O or NH; R 9 is H, hydroxyl or C 1-8 alkyl; R 10 is H or C 1-8 alkyl; R 11 is H or C 1-8 alkyl; and a is 0 or 1.